TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

doi:10.1182/bloodadvances.2025015834

Return

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

2025-05-05

Alexandra Traverse‐Glehen

Catherine Thiéblemont

Pierre Sesques *

DOI：10.1182/bloodadvances.2025015834

Original

Save

View PDF

Abstract

En 中文

• The outcome of relapsed/refractory TriNHL is better than that of relapsed/refractory de novo LBCL. • The toxicity profile of CAR T cells in relapsed/refractory TriNHL is acceptable.

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.